Pharmgate Animal Health has announced PRRSGard, an innovative, modified-live vaccine, has received U.S. Department of Agriculture approval extending expiratory dating from 18 to 24 months.
Eighteen months is the USDA standard for live vaccines, but our extended stability data confirm the product is stable, resulting in the approval of the 24-month expiration dating in November,” said Betsy Conarchy, biological regulatory affairs and quality manager for Pharmgate. “Producers and veterinarians now can have even more confidence in using the vaccine.
PRRSGard is a 1.0 milliliter, single-dose recombinant chimeric vaccine for Porcine Reproductive and Respiratory Syndrome (PRRSV). It features:
- An attenuated, lineage 1 PRRSV strain as a vaccine backbone
- A virulent, contemporary lineage 1 PRRSV field isolate, MN 184
- A non-encoding RNA sequence is inserted into the genome. This unique genetic marker allows diagnostic assay differentiation from “wild-type” virus strains.
The company said trials show that PRRSGard promotes broad cross-strain immunity, reduced lung lesions and viremia, a low vaccine virus shed and spread following a challenge. It has been shown to reduce performance loss from pneumonia associated with PRRSV in growing pigs.
Founded in 2008, Pharmgate Animal Health is headquartered in Wilmington, N.C., and provides innovative and high-quality products that help the livestock industry optimize animal health, efficiency and production.
The company’s pharmaceutical production facilities are in Omaha, Neb., with vaccine research and manufacturing operations based in St. Paul, Minn.